scholarly journals Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab‑paclitaxel chemotherapy: A case report

2019 ◽  
Author(s):  
Tetsuo Yokota ◽  
Shigetsugu Takano ◽  
Hideyuki Yoshitomi ◽  
Shingo Kagawa ◽  
Katsunori Furukawa ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Case Report ◽  
Cancer Patient ◽  
Successful Treatment ◽  
Interstitial Pneumonitis ◽  
Locally Advanced ◽  
Pancreatic Cancer Patient ◽  
Unresectable Pancreatic Cancer ◽  
Conversion Surgery

scholarly journals Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report

2019 ◽  
Vol 4 (1) ◽  
pp. 10-14
Author(s):  
Adam R. Wolfe ◽  
Rishi Jain ◽  
Timothy M. Pawlik ◽  
Jon Walker ◽  
Terence M. Williams
Keyword(s):  
Pancreatic Cancer ◽  
Case Report ◽  
Cancer Patient ◽  
Brca2 Mutation ◽  
Pancreatic Cancer Patient ◽  
Radiation Induced

Results of conversion surgery after the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic cancer.

2019 ◽  
Vol 37 (4_suppl) ◽  
pp. 366-366
Author(s):  
Naoya Ikeda ◽  
Takahiro Akahori ◽  
Sohei Satoi ◽  
Hiroaki Yanagimoto ◽  
Minako Nagai ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Clinical Impact ◽  
Ductal Adenocarcinoma ◽  
Unresectable Pancreatic Cancer ◽  
Conversion Surgery ◽  
Open Label ◽  
Grade 3 ◽  
Medical University

366 Background: Recent improvements in chemotherapy for initially unresectable pancreatic ductal adenocarcinoma (UPDAC) occasionally show remarkable antitumor effect and lead to conversion surgery (CS). However, the optimal indication and clinical impact of CS remains unknown. We have recently developed a new regimen consisted of biweekly S-1, oxaliplatin, and irinotecan (SOXIRI). In this regimen, we used S-1 in alternate-day administration instead of 5-FU, that can be more feasible than FOLFIRINOX. The aim of this study was to evaluate the clinical impact of CS after SOXILI treatment for initially UPDAC. Methods: We conducted an open-label, single-arm, phase II study that was carried out at Nara Medical University and Kansai Medical University in Japan. Patients with untreated metastatic and locally advanced PDAC were enrolled. They received 80 mg/m2 twice a day of S-1 for 2 weeks in alternate-day administration, 150 mg/m2 of irinotecan on day 1, and 85 mg/m2 of oxaliplatin on day 1 of a 2-week cycle. Results: The 35 enrolled patients received a median of six (range: 2-15) treatment cycles. The RR was 22.8%; median OS, 17.7 months; and median PFS, 7.4 months. Major grade 3 or 4 toxicity included neutropenia (54%), anemia (17%), febrile neutropenia (11%), anorexia (9%), diarrhea (9%), and nausea (9%). Twenty-three out of 35 patients of UR-PDAC were unresectable locally advanced pancreatic cancer (UR-LAPA). Seven out of 23 patients with UR-LAPA underwent CS. Distal pancreatectomy with celiac axis resection was performed in three patients, central pancreatectomy was performed in one patient. Pancreatoduodenectomy (PD) was performed in two patients, and PD with portal vein resection in one patient. Two out of seven patients had postoperative complications. One case had grade B pancreatic fistula, and the other case underwent cholecystectomy due to acute cholecystitis. The median OS in patients who received CS was 31.4 months. Conclusions: SOXIRI regimen has shown promising clinical efficacy with acceptable tolerability in patients with unresectable pancreatic cancer. Furthermore, it may be a potent first-line treatment when considering conversion surgery. Clinical trial information: UMIN000014339.

scholarly journals Prognosis and appropriate resection criteria of conversion surgery for locally advanced unresectable pancreatic cancer

HPB ◽  
2021 ◽  
Vol 23 ◽  
pp. S289
Author(s):  
Y. Ando ◽  
K. Okano ◽  
H. Matsukawa ◽  
H. Suto ◽  
M. Oshima ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Locally Advanced ◽  
Unresectable Pancreatic Cancer ◽  
Conversion Surgery

scholarly journals Current trends and issues of conversion surgery for patients with locally advanced unresectable pancreatic cancer

Suizo ◽  
2018 ◽  
Vol 33 (1) ◽  
pp. 48-55
Author(s):  
Toshimichi ASANO ◽  
Satoshi HIRANO ◽  
Toru NAKAMURA ◽  
Takehiro NOJI ◽  
Keisuke OKAMURA ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Locally Advanced ◽  
Unresectable Pancreatic Cancer ◽  
Conversion Surgery ◽  
Current Trends
Sign in / Sign up

Export Citation Format

Share Document